| Company Name: |
InvivoChem |
| Tel: |
+1-708-310-1919 +1-13798911105 |
| Email: |
sales@invivochem.cn |
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide manufacturers
- Mevociclib
-
- $199.00
-
2026-07-27
- CAS:1816989-16-8
- Purity: 98.02%
- Supply Ability: 10g
- Mevociclib
-
- $199.00
-
2026-07-27
- CAS:1816989-16-8
- Purity: 98.02%
- Supply Ability: 10g
|
| | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Basic information |
| Product Name: | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide | | Synonyms: | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide;SY-1365;SY 1365;SY1365;2-Pyridinecarboxamide, N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-;N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide;Mevociclib,SY-1365;Inhibitor,triple negative breast cancer,TNBC,Mevociclib,Cyclin dependent kinase,SY1365,tumors,cancers,cell,inhibit,solid,CDK,small,SY 1365,CDK7/CycH/MAT1,lung;N-[(1S,3R)-3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-1-methylcyclohexyl]-5-[(2E)-4-(dimethylamino)but-2-enamido]pyridine-2-carboxamide;Mevociclib | | CAS: | 1816989-16-8 | | MF: | C31H35ClN8O2 | | MW: | 587.11 | | EINECS: | | | Product Categories: | SY-1365 | | Mol File: | 1816989-16-8.mol |  |
| | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 125 mg/mL (212.90 mM) | | form | Solid | | pka | 12.04±0.70(Predicted) | | color | White to off-white |
| | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Usage And Synthesis |
| Uses | N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide is a CDK7 inhibitor and is used for anticancer treatments. | | in vivo | Mevociclib (20mg/kg; i.v.; biw; for 35 days) inhibits tumor growth in TNBC in vivo models[2].
Mevociclib induces unique transcriptional signature[2].
| Animal Model: | Mice, HCC70 xenograft model[2] | | Dosage: | 20 mg/kg | | Administration: | Intravenous injection, twice weekly, for 35 days | | Result: | Inhibited tumor volume in vivo. |
| | IC 50 | CDK7 |
| | N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Preparation Products And Raw materials |
|